Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A large real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) versus insulin glargine U300

Next Previous
Trial Profile

A large real-world evidence (RWE) study comparing the effectiveness of Tresiba® (insulin degludec injection) versus insulin glargine U300

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary) ; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms CONFIRM
  • Sponsors Novo Nordisk

Most Recent Events

  • 05 Oct 2018 Results comparing the real-world effectiveness of insulin degludec (degludec) and insulin glargine 300 units/mL (glargine U300) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
  • 29 Jun 2018 New trial record
  • 26 Jun 2018 Primary endpoint has been met. (Change in HbA1c of adult patients treated with Tresiba compared to those treated with insulin glargine U300. ( baseline to six months follow-up.)) as per results presented at the 78th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top